Loading patent…
OwnerKenichi Fujise, Nongporn Towatana +1inventors
InventorsKenichi Fujise, Nongporn Towatana, Wilawan Mahabusarakam
Estimating the term…
Provided herein are methods of treating postangiplasty, in-stent restenosis or atherosclerosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone with or with a effective dose of one or more of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent. Also provided are pharmaceutical compositions comprising a morelloflavone or pharmaceutical combinations comprising a morelloflavone and one of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent.
A method for treating postangiplasty or in-stent restenosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone.
A method for treating postangiplasty or in-stent restenosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone in a dose of from about 0.1 mg/kg to about 100 mg/kg of the individual's body weight.
A method for treating postangiplasty or in-stent restenosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone and an HMG-CoA reductase inhibitor.
A pharmaceutical composition comprising a morelloflavone and a pharmaceutically acceptable carrier therefor.
A pharmaceutical combination comprising a morelloflavone and one of:
A method for treating atherosclerosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone.
Dependencies are inferred from the claim text.